Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) FCF Margin (2016 - 2025)

Historic FCF Margin for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to 21.43%.

  • Arcadia Biosciences' FCF Margin rose 925600.0% to 21.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 117.57%, marking a year-over-year increase of 1338900.0%. This contributed to the annual value of 190.6% for FY2024, which is 1530200.0% up from last year.
  • Latest data reveals that Arcadia Biosciences reported FCF Margin of 21.43% as of Q3 2025, which was up 925600.0% from 138.9% recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' FCF Margin ranged from a high of 41.38% in Q4 2022 and a low of 627.05% during Q1 2021
  • Its 5-year average for FCF Margin is 238.16%, with a median of 188.28% in 2024.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 26247300bps in 2021, then crashed by -5756100bps in 2023.
  • Quarter analysis of 5 years shows Arcadia Biosciences' FCF Margin stood at 157.67% in 2021, then surged by 126bps to 41.38% in 2022, then plummeted by -1391bps to 534.23% in 2023, then surged by 66bps to 179.44% in 2024, then skyrocketed by 88bps to 21.43% in 2025.
  • Its FCF Margin was 21.43% in Q3 2025, compared to 138.9% in Q2 2025 and 133.33% in Q1 2025.